Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea

  • RedHill Biopharma Ltd (NASDAQ:RDHL) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea. 
  • Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payment of $1.5 million.
  • Redhill is eligible for up to $5.6 million in milestone payments and low double-digit royalties on net sales of oral opaganib in South Korea. 
  • Kukbo will receive the exclusive rights to commercialize opaganib in South Korea for COVID-19.
  • Related: RedHill Biopharma's Upamostat Shows 100% Efficacy In Non-Hospitalized COVID-19 Patients.
  • "Every day this month, we are seeing an average of almost 2000 people hospitalized due to COVID-19 in South Korea, and we desperately need medications that can effectively treat these patients," said Hyun Ha, Kukbo's CEO." 
  • The partnership with Kukbo also includes a right of the first offer for RedHill's opaganib, RHB-107 (upamostat), and Talicia for one or more of the territories of South Korea, Japan, Indonesia, Vietnam, Thailand and/or Malaysia, extended until the end of October 2022.
  • Price Action: RDHL shares are down 1.20% at $1.65 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.